Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up
about
Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodiesThe Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's DiseaseRecent advances in the neuropsychopharmacology of serotonergic hallucinogensEvidence for the use of pimavanserin in the treatment of Parkinson's disease psychosisPsychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's diseasePatterns and trends in antipsychotic prescribing for Parkinson disease psychosisPimavanserin for the treatment of Parkinson's disease psychosis.Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.Behavioral effects of levodopa.Lewy body dementias.Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?Pathophysiology and treatment of psychosis in Parkinson's disease: a review.Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelinesAn eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.An update expert opinion on management and research strategies in Parkinson's disease psychosisPresent and future drug treatment for Parkinson's disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Treatment of behavioural symptoms and dementia in Parkinson's disease.Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs.Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies.The management of psychosis in movement disorder patients.Management of the behavioral aspects of Parkinson's disease.Advances in the treatment of visual hallucinations in neurodegenerative diseases.Treatment options for non-motor symptoms in late-stage Parkinson's disease.Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia.Treatment of dementia with lewy bodiesUse of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital.Nonmotor symptoms in Parkinson's disease.Atypical antipsychotic drugs in the treatment of Parkinson's disease.5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.The serotonergic system in motor and non-motor manifestations of Parkinson's disease.Treating psychosis in movement disorder patients: a review.Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders.Psychiatric Conditions in Parkinson Disease: A Comparison With Classical Psychiatric Disorders.Therapy-resistant symptoms in Parkinson's disease.The psychosis spectrum in Parkinson disease.
P2860
Q24680260-0937489C-24E6-47B2-B321-C6597338150AQ26738456-36379FD6-7B88-4B55-9145-E2E2EA60E018Q27027381-2CC461F3-0FC9-4E10-923C-9F1C2FA61291Q28074468-49B6F68C-011D-48C6-BAB6-24AEDF6CD227Q30249553-D3E21B3C-4CD1-4778-92FD-2C28811E5B94Q30489967-9783F4E6-041B-4E5C-9B67-38D7C78379ABQ33607256-AE2A4E84-6053-450C-8E48-25F60870CB31Q33957582-C944D404-2F13-49CC-A179-50F8E670AFF6Q34369646-21545DDD-965E-4394-AAC8-FBCE417133DAQ34388686-A9F264AD-942F-4BCC-B9C5-C3001AB115AFQ34452922-EC088FA6-F09D-405E-9CFF-6ED89D71F232Q34502646-DB37F944-9B8C-4417-ABDE-D1AA82A5A79FQ34610593-FB374B9E-7CC6-4D3E-9F29-4C4DB241BD3EQ34610608-FFD9D9CF-EE9B-433E-BBE9-383561152749Q34758986-02876FF3-41E4-4365-9FE2-39E2C8B63B24Q35124915-9EC93AE2-EC4D-417B-9EE1-249F4E75F582Q35154278-8C0119EA-429E-411C-A066-660CE5F57F05Q35484805-9B424716-680C-41AA-BD00-D0B4F91FD2E4Q35614156-4ED70305-D7C8-4026-B1E9-26AB444D4DDEQ36089350-972C3CE2-8B28-41BA-8567-BF51517FB4C2Q36351543-B4267550-81B8-4E4A-9BDB-BAD5190E5C77Q36425995-4AD0796D-4B8C-4F10-AFCA-E00E4A844367Q36806669-899AABE8-DB66-44D5-AD30-5482263098B0Q36808034-7B9291D2-D455-4987-9B14-319A1DD25AC8Q36847271-94561992-7024-43C5-B78D-CC35F88EFB99Q37029454-C88BC643-23CF-445B-AFB8-FEF13892DE75Q37098986-1E43C0CB-5448-47B9-93AF-E841D160BEDFQ37166113-8C0E8EC9-28AB-4053-9719-FFE9E7569F57Q37552865-0D6AEBEF-2A22-46B5-B25A-009243CB4F26Q37862378-E72ABF52-AFE0-457D-A3F7-978596D33011Q37950422-E0217135-8766-4DEF-B474-C7667052C6B5Q37957772-C783CA08-110A-4E2C-864D-1FB146883189Q38081485-453F63ED-3FE3-405B-9DE8-337B2098D0CEQ38118061-CDA40DD7-0392-4A07-B37B-07BAC988DEE2Q38213306-0C6FB052-459E-4A30-B4A2-C395264D4F30Q38258699-E3592B93-A5CC-4130-9175-58EB57163CD4Q38260932-124932C2-1110-4BA6-9AD4-2FF6E2C49E90Q38588201-FE1F1D2C-4698-4D52-A223-547BC9E701C5Q38593798-B6B4E9D4-36F4-4E34-B2FC-BE0DC0E4F83CQ38768169-D07A907A-324E-4CEC-8BE2-ACF658717971
P2860
Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clozapine in drug induced psyc ...... lled study with open follow up
@ast
Clozapine in drug induced psyc ...... lled study with open follow up
@en
type
label
Clozapine in drug induced psyc ...... lled study with open follow up
@ast
Clozapine in drug induced psyc ...... lled study with open follow up
@en
prefLabel
Clozapine in drug induced psyc ...... lled study with open follow up
@ast
Clozapine in drug induced psyc ...... lled study with open follow up
@en
P2093
P2860
P921
P356
P1476
Clozapine in drug induced psyc ...... lled study with open follow up
@en
P2093
Bourdeix I
P2860
P304
P356
10.1136/JNNP.2003.029868
P407
P577
2004-05-01T00:00:00Z